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RESUMO 
 A deficiência de guanidinoacetato metiltransferase (GAMT) é um erro inato do 
metabolismo (EIM) detectado entre as síndromes da deficiência de creatina, sendo 
causada por uma mutação no gene que codifica a enzima GAMT, o que leva a uma 
diminuição na síntese de creatina e um consequente aumento na concentração de 
guanidinoacetato (GAA). Pessoas que sofrem dessa síndrome começam a 
apresentar sintomas neurológicos na infância como: hipotonia muscular, movimentos 
extrapiramidais involuntários e convulsões. O objetivo geral do presente projeto foi 
estudar a neurotoxicidade do GAA, através de estudo do comportamento (teste de 
reconhecimento de objetos), atividade da enzima acetilcolinesterase (AChE) e testes 
bioquímicos de estresse oxidativo (enzimas antioxidantes e oxidação da 2,7-
diclorofluoresceína), bem como o papel da creatina como neuroprotetora utilizando 
um modelo de cirurgia estereotáxica em ratos adultos. Ratos Wistar de 60 dias de 
vida foram submetidos a cirurgia estereotáxica após um pré-tratamento com creatina 
ou salina que durou 7 dias. Após a cirurgia os animais receberam uma administração 
intraestriatal sendo divididos em quatro grupos: (1) controle (infusão intraestriatal 
de salina e pré-tratamento com salina), (2) Salina + GAA (infusão intraestriatal de 
GAA e pré-tratamento com salina), (3) Creatina + GAA (infusão intraestriatal de 
GAA e pré-tratamento com creatina), (4) Creatina + Salina (infusão intraestriatal de 
salina e pré-tratamento com creatina). Uma hora após a administração intraestriatal os 
ratos foram decapitados para análise bioquímica do estriado ou submetidos ao teste 
comportamental. Resultados mostraram que a administração intraestriatal de GAA foi 
capaz prejudicar a performance de ratos no teste de reconhecimento de objetos, 
além de aumentar a atividade da AChE, aumentar a produção de espécies reativas e 
diminuir a atividade de enzimas antioxidantes. Creatina se mostrou capaz de 
prevenir a maioria das alterações, com exceção da diminuição da atividade da 
enzima superóxido dismutase (SOD). É possível supor que as alterações 
bioquímicas aqui encontradas contribuem para as alterações neurológicas 
apresentadas por pacientes com deficiência de GAMT. É possível que a 
suplementação com creatina possa ser um tratamento adjuvante.  
 Palavras chave: Deficiência de guanidinoacetato metiltransferase; Creatina; 
Guanidinoacetato; Neurotoxicidade; Acetilcolinesterase; Estresse oxidativo 
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1. INTRODUÇÃO 
 
 1.1 Erros inatos do metabolismo 
 
 Erros inatos do metabolismo (EIM) são doenças genéticas hereditárias, 
majoritariamente autossômicas recessivas que se caracterizam pela síntese de uma 
proteína anômala, geralmente uma enzima, que apresentará atividade parcial ou 
totalmente reduzida. Essas alterações podem levar ao bloqueio de rotas metabólicas com 
consequente acúmulo de substrato, diminuição na síntese do produto ou até formação de 
produtos tóxicos por rotas metabólicas alternativas (Scriver, 2008). 
 Os EIM são considerados raros quando analisados separadamente, porém, em 
conjunto, os cerca de 1000 EIM descritos atingem um a cada mil nascidos vivos (Mak et 
al., 2013). A classificação mais utilizada para os EIM é realizada de acordo com a área do 
metabolismo afetada (Scriver, 2001), podendo ser: EIM de ácidos orgânicos, 
aminoácidos, glicídios, lipídios, glicosaminoglicanos, glicoproteínas, purinas e pirimidinas, 
enzimas eritrocitárias, metais, lipoproteínas, hormônios e proteínas plasmáticas, dentre 
outros.  
 A deficiência da Guanidinoacetato Metiltransferase (GAMT) foi o primeiro EIM 
detectado entre as síndromes da deficiência de creatina, sendo o foco deste trabalho. 
 
 1.2 Deficiência de Guanidinoacetato Metiltransferase (Deficiência de GAMT) 
 
 O N-amino-imino-metil-glicina, conhecido como guanidinoacetato (GAA) é um 
aminoácido pertencente à classe dos compostos guanidínicos. Esses compostos são 
substâncias caracterizadas pela presença do grupo básico guanidino em sua estrutura 
(H2N-C(=NH)-NH-), e exercem um importante papel biológico, incluindo a participação da 
arginina na síntese de uréia e da creatina na contração muscular (Wyss et al., 2007).  
 O GAA é sintetizado nos rins, onde é obtido principalmente da arginina e glicina 
(Takeda et al., 1992). Após a síntese renal, é transportado pelo fígado, onde recebe um 
grupamento metil doada pela S-adenosilmetionina (SAM), em uma reação catalisada pela 
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enzima Guanidinoacetato Metiltransferase (GAMT)., dando origem à creatina (Gordon, 
2010).  
 A deficiência de GAMT foi o primeiro EIM detectado entre as síndromes da 
deficiência de creatina, sendo descrita como de natureza genética hereditária, causada 
por uma mutação no gene que codifica a enzima GAMT, o que leva a uma diminuição na 
síntese de creatina e um consequente aumento na concentração de GAA (Stöckler, et al., 
1994; Stöckler, et al., 1996; Schulze, et al., 2001; Gordon, 2010). As alterações 
bioquímicas decorrentes desse EIM incluem excreção urinária contendo muito GAA e 
pouca creatina, altas concentrações de GAA no cérebro e em outros tecidos, e redução 
drástica de creatina no cérebro e nos músculos esqueléticos dos pacientes afetados 
(Stöckler, et al., 1996; Schulze, et al., 2003). Pessoas que sofrem dessa síndrome 
começam a apresentar sintomas neurológicos na infância como: hipotonia muscular, 
movimentos extrapiramidais involuntários, convulsões, fala arrastada e até mesmo 
autismo (Stöckler, et al., 1996; Schulze, et al., 2001; Arias-Dimas, et al., 2006; Gordon, 
2010). 
 
 
Figura 1. Bloqueio metabólico no metabolismo da creatina encontrado da deficiência de 
GAMT. Abreviações: AGAT, arginina: glicina-amidinotransferase; GAMT, 
guanidinoacetato metiltransferase; ATP, adenosina trifosfato; ADP, adenosina difosfato; 
CK, creatina quinase. Adaptado de Casey and Greenhaff, 2000. 
 Diversos estudos buscam opções de tratamentos para aliviar os sintomas 
apresentados pelos pacientes com deficiência de GAMT. A suplementação oral de 
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creatina em doses de 400-670 mg por kg de peso corporal por dia pode resultar em 
melhoras, principalmente no quadro de movimentos involuntários extrapiramidais e 
ataques epiléticos. Apesar de um recente estudo demonstrar que suplementação com 
creatina diminui os níveis plasmáticos de GAA em indivíduos normais (Peters et al, 2015), 
é importante ressaltar que  o mesmo não parece ocorrer em pacientes com deficiência na 
enzima GAMT (Stöckler, et al., 1996; Gordon, 2010). Para que haja uma melhora ainda 
maior no quadro clínico, estudos sugerem que uma diminuição na ingestão de um dos 
aminoácidos precursores do GAA, a arginina, combinada com suplementação de ornitina 
também podem prevenir as convulsões características da doença (Dhar et al., 2009; 
Gordon, 2010; Stockler et al., 2014).  
 
 1.3 Creatina 
 
 A creatina é um ácido orgânico nitrogenado que exerce diversos papéis 
benéficos in vivo e in vitro, tais como efeitos protetores na hipóxia, isquemia cerebral, 
dano muscular, e oxidativo (Wyss, et al., 2007; Andres, et al., 2008). Sua suplementação 
pode inclusive ser utilizada como estratégia para o crescimento e a manutenção muscular 
e óssea (Schlattner, et al., 2006). Muitos de seus efeitos benéficos provêm da ação da 
enzima creatina cinase (CK) sobre a creatina, o que gera a fosfocreatina, que é de 
extrema importância para diversos processos metabólicos, funcionando como reserva 
energética, transferindo reversivelmente seu grupo N-fosforil para o ADP quando este 
está em altas concentrações, regenerando assim ATP (Wallimann, et al., 1992; Saks, et 
al., 2004; Sauer e Schlattner, 2004). Aproximadamente dois terços da creatina são 
transformados em fosfocreatina pelas isoformas de CK (Wallimann, et al., 2011). Somado 
a isso, a creatina possui propriedades antioxidantes per se (Sestili, et al., 2006; Young, et 
al., 2010) e sua suplementação possui ação neuroprotetora em doenças 
neurodegenerativas (Wyss e Schulze, 2002; Hersch, et al., 2006; Bolaños, et al., 2009; 
Pastula, et al., 2012). A reserva energética fornecida pelo sistema creatina/creatina 
quinase também ajuda a prevenir a sobrecarga da cadeia transportadora de elétrons, 
reduzindo a geração de espécies reativas que tem o poder de causar estresse oxidativo e 
induzir a dissociação do citocromo C da membrana interna mitocondrial, evitando eventos 
de ativação da apoptose, o que sugere proteção cerebral ao acúmulo de GAA (Kolling e 
Wyse, 2010; Meyer et al, 2006). 
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1.4 Acetilcolinesterase 
 
A acetilcolina (ACh) é um neurotransmissor clássico sintetizado pela enzima colina 
acetiltransferase a partir de acetato e colina, sendo armazenado em vesículas nos 
neurônios pré-sinápticos. A acetilcolinesterase (AChE) é uma enzima responsável pela 
degradação da ACh liberada na fenda sináptica, e que parece ajudar a co-regular a 
transmissão colinérgica (Geula e Darvesh, 2004). Diversos estudos apontam que esta 
enzima desenvolve papéis importantes em várias desordens neurológicas, inclusive na 
doença de Alzheimer (Giacobini, 2004; Lane, et al., 2004; Lane, et al., 2006; Sindi, et al., 
2015). Inibidores da AChE permitem que o neurotransmissor ACh permaneça mais tempo 
na fenda sináptica, o que promove acentuada melhora no aprendizado e memória em 
ratos isquêmicos tratados com anticolinesterásicos (Borlongan, et al., 2005).  
Por desempenhar um papel fundamental no SNC e coordenar propriedades anti-
inflamatórias que podem evitar um estado de estresse oxidativo, é importante que a 
atividade da AChE esteja regulada, já que poderia trazer consequências neurológicas 
indesejadas. Entretanto, estudos apontam que compostos guanidínicos, como o GAA, 
alteram a atividade dessa enzima (Delwing-De Lima, et al., 2010), levando inclusive a 
alterações comportamentais (Zugno, et al., 2008), o que pode estar associado com as 
alterações neurológicas presentes nos pacientes deficientes em GAMT. 
Embora a fisiopatologia da deficiência de GAMT seja pouco conhecida, algumas 
alterações bioquímicas e comportamentais já foram observadas em alguns estudos. 
Neste contexto, ratos submetidos à cirurgia estereotáxica, que receberam uma injeção 
intraestriatal de GAA, decapitados 30 min após essa injeção, tiveram um aumento na 
atividade da AChE, além de apresentarem um prejuízo na aquisição, consolidação e 
evocação da memória aversiva, sugerindo que o GAA afeta todos os passos da formação 
da memória (Zugno, et al., 2008). Portanto, é de nosso interesse elucidar os mecanismos 
responsáveis por essas alterações. 
 
 
1.4 Estresse Oxidativo 
 
As espécies reativas são constantemente produzidas no organismo em níveis 
basais, principalmente durante o processo de respiração celular, e possuem diversas 
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funções fisiológicas (Halliwell, 2012). O organismo possui diversos mecanismos para 
evitar que os efeitos das espécies reativas se tornem muito prejudiciais ao nosso corpo, 
entre eles estão as defesas enzimáticas (Superóxido Dismutase [SOD], Catalase [CAT] e 
Glutationa Peroxidase [GPx]) e as não-enzimáticas (Glutationa reduzida [GSH], vitaminas, 
entre outras) (Halliwell e Gutteridge, 2007). Entretanto, em situações patológicas essas 
espécies reativas podem causar um desequilíbrio entre as espécies reativas e as defesas 
antioxidantes. A persistência desse desequilíbrio leva ao estresse oxidativo, que pode 
causar dano em diferentes tipos de biomoléculas, incluindo DNA, lipídeos e proteínas 
(Halliwell e Whiteman, 2004; Nelson e Cox, 2008). Além disso, o estresse oxidativo pode 
desencadear respostas inflamatórias locais e sistêmicas, que por sua vez intensificarão o 
próprio estresse oxidativo.  
O cérebro é um órgão sensível ao estresse oxidativo, uma vez que o sistema 
nervoso central (SNC) apresenta um elevado consumo de oxigênio em consequência do 
alto consumo de ATP. Nesse sentido, existem diversas evidências que apontam a 
correlação entre o estresse oxidativo e a ocorrência de doenças neurodegenerativas, tais 
como Parkinson, Alzheimer, esclerose lateral amiotrófica, epilepsia, entre outras (Halliwel, 
2001; Moreira, et al., 2005; Vidoni et al., 2016). 
Estudos do nosso grupo já demonstraram que o excesso de GAA inibe a atividade 
da creatina cinase, o complexo II da cadeira respiratória e a captação de glutamato, 
provavelmente através de estresse oxidativo (Zugno, et al., 2007; Zugno, et al., 2007).  
 
 
2. OBJETIVOS 
 
2.1.     Objetivo geral 
 
 O objetivo geral do presente projeto foi estudar os mecanismos de neurotoxicidade 
do GAA, incluindo estudos bioquímicos e comportamentais, bem como o papel da 
creatina como neuroprotetora. 
 
2.2.     Objetivos específicos  
  
 1) Avaliar a memória/aprendizado de ratos submetidos à administração 
intraestriatal de GAA, utilizando a tarefa comportamental de reconhecimento de objetos;   
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 2) Investigar parâmetros bioquímicos que possam estar envolvidos nas possíveis 
alterações de memória e comportamento, tal como atividade da AChE em estriado de 
ratos submetidos à injeção instraestriatal de GAA; 
 3) Avaliar alguns parâmetros de estresse oxidativo, tais como: atividade das 
enzimas antioxidantes (SOD e CAT) e oxidação da 2,7-dicloro fluoresceína (DCF) em 
estriado de ratos submetidos à injeção instraestriatal de GAA; 
 4) Investigar o papel neuroprotetor da creatina sobre as alterações bioquímicas e 
comportamentais encontradas no presente estudo. 
 
 Os resultados, bem como a metodologia do trabalho serão mostrados na forma de 
artigo científico a ser submetido para uma revista científica; 
  
  Além do trabalho experimental também foi escrito uma revisão sobre o tema - ver 
anexo A. 
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3.     ARTIGO CIENTÍFICO  
 O artigo intitulado ―Effect of guanidinoacetate on memory and oxidative status 
in striatum‖ foi formatado conforme normas para publicação junto ao periódico Journal of 
Inborn Errors of Metabolism & Screening
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Abstract 
 Guanidinoacetate Methyltransferase deficiency is a disorder of  the creatine 
metabolism, altering guanidinoacetate (GAA) and creatine levels. Patients present 
convulsions and mental retardation, whose mechanisms are unclear. In this study 
we investigated the effects of an intrastriatal administration of GAA on non-aversive 
behavioral test, acetycholinesterase (AChE) activity and parameters of oxidative 
stress such as 2′7′dichlorofluorescein (DCFH) oxidation and antioxidant enzyme 
activities. Adult rats received a single intrastriatal GAA administration or saline. 
Animals were subjected to behavioral or striatum biochemical tests 1 hour after the 
infusion. In the novel object recognition test, the time exploring the novel object 
increased in the control group (P < 0.05), while the same did not happened in 
treated animals. GAA significantly increased AChE (P < 0.01) and decreased the 
activity of Superoxide dismutase (SOD) (P < 0.01) and catalase (CAT) (P < 0.01)  
as well as increased DCF oxidation (P < 0.01) Creatine prevented all alterations, 
except SOD activity. 
 
 
 
 
 
 
Key words: Guanidinoacetate Methyltransferase – GAMT Deficiency; 
Creatine; Guanidinoacetate; Neurotoxicity; Acetylcholinesterase; Oxidative stress
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3.1     Introduction 
Guanidinoacetate (GAA) is a metabolite of glycine in which the amino 
group can be converted into a guanidine. It is highly involved in the metabolism 
of creatine, being its direct precursor. 1   
Creatine   has   been   known   for   its   essential   functions   in   muscle, 
contributing to a transient intracellular storage of metabolic energy mainly in the 
form of phosphocreatine that is nothing more than creatine with a phosphate 
group.1 Mammals take about half of their creatine from diet (mostly from meat 
and fish), and synthesize the other half through a relative simple reaction that 
occurs mainly in the kidney and liver involving a two-step pathway with two 
enzymes and one membrane carrier.² The enzymes involved are L-arginine: 
glycine amidinotransferase (AGAT) and N-guanidinoacetate methyltransferase 
(GAMT), while the membrane carrier is named SLC6A8. The phosphorylation of 
creatine is made possible by the creatine kinases (CK).3 This is an efficient way 
to store energy not only to skeletal muscle, but also to organs that require a 
great amount of energy in order to efficiently develop their activities in human 
body, like the brain.4 The phosphocreatine has a slightly higher diffusion 
capacity than ATP, and it can reversibly transfers its N-phosphoryl group to ADP 
when this nucleotide is at high concentrations, regenerating ATP and 
preventing the tissue from running out of energy. 5,6,7.  
In 1994, Stöckler et al, described a new inborn error of metabolism (IEM) 
that was addressed as the first inborn error of metabolism of creatine. The new 
disease was named after the affected enzyme: guanidinoacetate 
methyltransferase (GAMT) deficieny.8  This metabolic disease is an autosomal 
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recessively inherited disorder caused by mutations in the GAMT gene that leads 
to depleted levels of creatine and excessive concentrations of GAA in skeletal 
muscle, blood, brain and other tissues.9,10,11  It  is  a  rare  disease  with  
approximately  110  cases reported so far, mostly from Europe and the Middle 
East.12 The cerebral tissue relies upon a continuous energy supply in order to 
maintain its functions properly. Therefore, with creatine in low levels, the brain 
becomes the most affected organ in GAMT deficiency patients. Neurological 
symptoms are common and variable among individuals affected by GAMT 
deficiency, including intractable epilepsy, intellectual impairment, autism, auto 
mutilating behavior, extra pyramidal syndrome, slurred speech and hypotonia. 
11,13,14,15 
Supplementation with creatine has been used as pharmacological 
treatment in GAMT deficiency for a long time.11 The energetic reservoir provided 
by the system creatine/creatine kinase helps to prevent the overload of the 
mitochondrial respiratory chain, reducing generation of reactive species that 
have the power to cause oxidative stress and induce cytochrome C dissociation 
from the inner mitochondrial membrane, initiating early apoptotic triggering 
events.16  A recent study revealed that creatine is able to prevent damage induced 
in  vitro  by  oxidizing  agents  in  both  nucleated  and  non-nucleated  cells, 
suggesting   that   creatinine   may   possess   similar   properties.20 These 
antioxidant proprieties presented by creatine appear to be beneficial not only to 
GAMT,21 but also to other innate errors of metabolism where creatine was able to 
prevent lipid peroxidation and imbalance of redox homeostasis.22,23 
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The cholinergic system plays a key role in the modulation of learning and 
memory in mammals24 and is also related with modulation of inflammatory 
pathways25. Achetylcholinesterase (AChE) is the enzyme responsible for the 
degradation of acetylcholine (ACh) released in the synaptic cliff, and has a role in 
the co-regulation of cholinergic transmission26. Several studies have shown that 
this enzyme plays an important role in several neurological disorders27,28. For 
developing a fundamental role in the central nervous system (CNS) and regulating 
anti-inflammatory properties that can avoid oxidative stress, it is important that the 
activity of this enzyme remain regulated, since it could bring unwanted 
neurological consequences. However, studies claim that guanidine compounds, 
like GAA,  alter the activity of AChE, leading to behavioral abnormalities 29, 30 that 
may be associated with the neurological alterations found in patients with GAMT 
deficiency. 
3.2 Aim 
In the present study, we investigated the effects of an intrastriatal 
administration of GAA on the process of memory acquisition (via novel object 
recognition tasks), as well as AChE activity in striatum adult rats.  We also 
evaluated some parameters of oxidative stress such as 2′7′dichlorofluorescein 
(DCFH) oxidation and antioxidant enzyme activities. The neuroprotective role of 
creatine on the possible biochemical changes observed in this model was also 
investigated. Our hypothesis is that the alterations caused by GAA may be 
associated with oxidative insult and that creatine might prevent such damage. 
Striatum was used because patients with GAMT deficiency present basal ganglia 
abnormalities31.  
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3.3     Materials and Methods 
3.3.1     Animals and reagents 
 Sixty-day-old wistar rats weighing 180–200 g were obtained from the 
Central Animal House of the Department of Biochemistry, Institute of Basic 
Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, RS, 
Brazil. Animals were maintained on a 12/12 h light/dark cycle in an air-
conditioned constant temperature (22 ± 1°C) colony room. Rats had free access 
to a 20% (w/w) protein commercial chow and water. Animal care followed the 
official governmental guidelines in compliance with the Federation of Brazilian 
Societies for Experimental Biology and was approved by the Ethics Committee 
of the Federal University of Rio Grande do Sul, Brazil. All efforts were made to 
minimize the number of animals used and their suffering. The chemicals were 
purchased from Sigma Chemical Co., St. Louis, MO, USA. 
 3.3.2    Pretreatment with creatine 
 The animals used for experiments in this study were subjected to a 
pretreatment for 7 days, receiving a daily intraperitoneal injection of creatine 
(50 mg/kg), or saline.32 During this pretreatment, stereotaxic surgery was 
performed in the animals in order to facilitate the administration of GAA, as 
described below. 
 3.3.3     Surgery and intrastriatal administration 
 Surgery and intrastriatal infusion were performed, according to 
Folbergrova et al. (2001). Animals were anesthetized by intraperitoneal injection 
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of ketamine and xylazine (100 mg/kg and 14 mg/kg, respectively). The heads of 
the animals were fixed in a stereotaxic apparatus, the skin of the skull was 
removed and a 27-gauge 9-mm guide cannula was then placed above the 
striatum (AP: −0.5 mm; L: −2.5 mm; DV: −2.5 mm). The cannula was fixed with 
acrylic cement. Experiments were performed at 48 h after surgery. A 30-gauge 
cannula was fitted into the guide cannula and connected by a polyethylene tube 
to a 5 μL Hamilton micro syringe. The tip of the infusion cannula protruded 
1.0 mm beyond the guide cannula towards the striatum.33 
 The animals were divided into four groups: Group 1 (control group), rats 
that suffered surgery and received intrastriatal infusion of saline and 
pretreatment with saline;  group 2 (GAA-treated), rats that received 10 μM 
intrastriatal infusion of GAA solution (0.02 nmol/striatum) and pretreatment with 
saline; group 3 (GAA-treated plus creatine), rats that received 10 μM intrastriatal 
infusion of GAA solution (0.02 nmol/striatum) and pretreatment with creatine; 
group 4 (Saline-treated plus creatine), rats that received intrastriatal infusion of 
saline and pretreatment with creatine. The volume administered intrastriatally 
(saline or GAA solution) was 2 μL. One hour after  intrastriatal infusion, the rats 
were decapitated without anesthesia (for biochemical studies) or subjected to 
the behavioral assessment. 
 3.3.4     Behavioral procedures  
 Behavioral procedures were performed between 10 a.m. to 3 p.m. in a 
controlled light and sound room, by a researcher blind to the animal‘s 
experimental condition. GAA was injected before the training session, in order to 
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evaluate the process of memory acquisition. The test session was performed 1h 
after the training to assess short-term memory. 
 One day before the training session, all animals were habituated to walk 
freely in the empty arena for 5 min. The arena used was a black wooden box 
(50 × 50 × 50 cm). In the training session, two identical objects were placed 
equidistant from the sidewalls. In this chamber, each animal performed a trial of 
5 min. After each trial, the apparatus was cleaned to alleviate olfactory cues. In 
the second trial, the test session, one of the objects was substituted by a different. 
An experimenter registered the time of object exploration, i.e., touching it with 
paws or exploring it by olfaction with direct contact of the snout 34. The object 
discrimination index was calculated in the test session, as follows: the difference 
in exploration time divided by the total time spent exploring the two objects 
{[(B − A)/(A + B)] where B is the new object and A is the familiar object}. Rats 
without memory impairment explore the new object for more time when compared 
with the old one 35.  
 3.3.5     AChE activity assay 
AChE activity was determined by the method of Ellman et al.40 For 
AChE assay, striatum was homogenized in ten volumes of 0.1 mM potassium 
phosphate buffer, pH 7.5, and centrifuged for 10 min at 1000 × g, being the 
supernatants used for the enzymatic AChE analyses.  Hydrolysis rate was 
measured at acetylthiocholine (S) concentration of 0.8 mM in 1 ml assay 
solutions with 100 mM phosphate buffer (pH 7.5) and 1.0 mM DTNB. Fifty 
microliters of striatum homogenate was added to the reaction mixture and 
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preincubated for 3 min. The hydrolysis was monitored by formation of the 
thiolate dianion of DTNB at 412 nm for 2–3 min (intervals of 30 s) at 25°C. All 
samples were run in duplicate. Protein was measured by the Coomassie Blue 
method according to Bradford.41 
 3.3.6     Oxidative stress parameters 
  3.3.6.1 Tissue Preparation 
  The striatum was homogenized in 10 volumes (1:10, w/v) of 20 mM 
sodium phosphate buffer, pH 7.4 containing 140 mM KCl, to determine the 
oxidative stress parameters. The homogenate was centrifuged at 750 × g for 
10 min at 4 °C; the pellet was discarded and the supernatant was immediately 
separated and used for the measurements. 
  3.3.6.2  2′,7′-dichlorofluorescein (H2DCF) oxidation assay 
  Reactive species production were measured second to LeBel et al. 
(1992) method 36, based on the oxidation of 2′,7′-dichlorofluorescein (H2DCF). 
Samples (60 μL) were incubated for 30 min at 37 °C in the dark with 240 μL of 
100 μM 2′,7′-dichlorofluorescein diacetate (H2DCF-DA) solution in a 96 wells 
plate. H2DCF-DA is cleaved by cellular esterases and the resultant H2DCF is 
eventually oxidized by reactive species presenting in samples. The last reaction 
produces the fluorescent compound dichlorofluorescein (DCF) which was 
measured at 488 nm excitation and 525 nm emission and the results were 
represented by nmol DCF/mg protein. 
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  3.3.6.3  Superoxide dismutase assay (SOD) 
  SOD activity assay is based on the auto-oxidation ability of 
pyrogallol, a process highly dependent on superoxide, which is the substrate for 
SOD. The inhibition of this compound autoxidation occurs in the presence of SOD, 
whose activity is then indirectly assayed at 420 nm using SpectraMax M5/M5 
Microplate Reader (Molecular Devices, MDS Analytical Technologies, Sunnyvale, 
CA, USA) 37. A calibration curve was performed with purified SOD as standard, in 
order to calculate the activity of SOD present in the samples. The results were 
reported as units per mg of protein. 
 
  3.3.6.4  Catalase assay (CAT) 
  CAT activity was assayed using SpectraMax M5/M5 Microplate 
Reader (Molecular Devices, MDS Analytical Technologies, Sunnyvale, CA, USA). 
The method is based on the disappearance of H2O2 at 240 nm in a reaction 
medium containing 20 mM H2O2, 0.1% Triton X-100, 10 mM potassium phosphate 
buffer pH 7.0, and 0.1–0.3 mg protein/mL 38. One CAT unit is defined as one μmol 
of hydrogen peroxide consumed per minute and the specific activity is calculated 
as CAT units/mg protein. 
 
  3.3.6.5  Protein determination 
  Protein concentration was measured by the method of Lowry et al. 
using bovine serum albumin as standard. 39 
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3.3.7     Statistical analysis 
 The parametric data for four groups were analyzed by one-way analysis of 
variance (ANOVA) followed by post hoc Tukey test when F-test was significant. 
Values of P < 0.05 were considered statistically significant. All analyzes and 
graphics were performed using GraphPad Prism 5.1 software program in a 
compatible computer. 
 
3.4    Results  
In the object recognition test, control rats spent less time on the familiar 
object in the test session when compared to the training (Figure 1A and 1B), 
thus, the time exploring the novel object increased in the control group (P ≤ 
0.05),  while the same did not happened in animals that received intrastriatal 
infusion of GAA. Creatine per se exerts no effect on this parameter and when 
associated with GAA was able to prevent the alterations (P ≤ 0.01). The group 
treated with GAA also exhibited a reduced discrimination index (p < 0.05) 
(Figure 1C). 
We evaluated the effect of GAA intrastriatal infusion and/or creatine 
administration on AChE activity in striatum of 60-day-old rats. Figure 2 shows 
that GAA infusion increased AChE in rat striatum (P ≤ 0.01) after 1h from the 
infusion. Creatine treatment per se did not alter this parameter, but prevented 
the effect caused by GAA. 
Since AChE can be altered by oxidative stress, we also investigated the 
effect of GAA intrastriatal infusion and/or creatine administration on antioxidant 
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enzymes, superoxide dismutase (SOD), catalase (CAT), and on reactive species 
production indicated by the 2′,7′-dichlorofluorescein (DCFH) oxidation. Figure 3 
shows that GAA infusion significantly decreased the activity of SOD (P ≤ 0.01) in 
rat striatum after 1h from the infusion, and that creatine was not able to reverse 
such alteration (P ≤ 0.001). As we can see in Figure 4, GAA intrastriatal infusion 
also caused a decline in CAT activity (P≤ 0.01) under the same circumstances. 
In this case creatine was able to prevent the alteration and did not altered the 
activity of this enzyme per se. Furthermore, the reactive species production was 
increased in rats that suffered GAA intrastriatal infusion when compared with 
control group (P≤ 0.01) (Figure 5). Once again, creatine treatment per se did not 
alter this parameter, but prevented the effect caused by GAA. 
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3.5     Figures 
Figure 1 
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Figure 2 
 
Figure 3 
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Figure 4 
 
Figure 5 
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3.6     Discussion 
Patients with (GAMT) deficiency present depleted levels of creatine and 
excessive concentrations of GAA in skeletal muscle, blood, brain and other 
tissues.9,10,11  Neurological symptoms are common and variable among 
individuals affected by GAMT deficiency, including intractable epilepsy, 
intellectual impairment, autism, auto mutilating behavior, extra pyramidal 
syndrome, slurred speech and hypotonia. 11,13,14,15 In this sense,  the brain 
becomes the most affected organ in GAMT deficiency patients, but the 
pathophysiology of this disease is still unclear. 
In the present study, we investigated the effects of an intrastriatal 
administration of GAA on the process of memory acquisition (via novel object 
recognition tasks), AChE activity, an important enzyme related with learning and 
memory29,30, as well as some parameters of oxidative stress such as 
2′7′dichlorofluorescein (DCFH) oxidation and antioxidant enzyme activities 
(SOD, CAT) in striatum of Sixty-day-old wistar rats. Furthermore we 
investigated the role of creatine on the possible biochemical changes observed 
in this model, since supplementation with creatine has been used as 
pharmacological treatment in GAMT deficiency for a long time.11 
Results show that rats that suffered an intrastriatal infusion of GAA had 
their performance in the novel object recognition test impaired. This is in 
agreement with previous data that also found learning and memory deficits in 
rats subjected to the same model.45 Nonetheless, the cholinergic system plays a 
crucial role in cognitive function, including memory.45 Previous studies have 
shown that cholinergic neurotransmission modulates aversive conditioning.46 
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Our results showed that GAA significantly increased AChE activity, implying 
that GAA accumulation affects memory processing, and that AChE probably 
plays a role in this alteration.  
Free radicals formation seems to be involved in a large number of human 
diseases. Due to accumulation of toxic metabolites, inborn errors of metabolism 
consist in diseases where this excessive free radical formation is almost always 
present. Aerobes constantly make reactive species, but modulate their actions 
by synthesizing antioxidants. This balance allows some reactive species to 
perform useful functions while minimizing oxidative damage43. However, this is 
not the case on this model. Results showed that GAA intrastriatal infusion 
increased DCF oxidation, an index of reactive species production. In addition to 
this, the activities of the antioxidant enzymes SOD and CAT were impaired. 
Studies have shown that an intrastriatal injection of GAA in rats inhibits the 
activity of crucial enzymes for the generation of energy in the CNS. These 
enzymes are Na+, K+-ATPase, complex II in the mitochondrial respiratory chain 
and creatine kinase.42,44 Alterations in such important enzymes may lead to 
depleted ATP availability, intensifying the overload of the mitochondrial 
respiratory chain, and increasing even more the occurrence of oxidative stress.  
The cognitive decline observed in this study is probably not caused 
by a single factor like AChE, but by a range of mechanisms that must be 
considered.47 GAA seems to act as a direct agonist of GABAA receptors with a 
less efficient GABA-mimetic potential than GABA itself. However, at high 
concentrations, like the ones found in GAMT patients, GAA is able to cause 
chronic stimulation in GABAA and, consequently, receptors undergo 
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desensitization. This effect causes an increase in neuronal excitability due to 
internalization of GABAA receptors and a decreased response to GABA.
48,49  
Creatine has been shown as a safe approach in the prevention and 
treatment of central nervous system disorders, such as neurodegenerative 
diseases and cognitive impairments. 50 Considering that more studies are 
necessary to establish the effects of creatine on experimental models, we also 
evaluated the effect of this compound on impairments elicited by GAA 
intrastriatal administration. Creatine concurrent administration prevented the 
effects caused by GAA in the activity of CAT and in the DCF oxidation, but had 
no effect on SOD decrease. Furthermore, creatine was able to prevent the 
increase in AChE activity, allowing ACh to remain for more time in the synaptic 
cliff, improving the outcome in the object recognition test. In this context, studies 
report that creatine may be a cytoprotector independent of the antioxidant status 
of enzymatic defenses, indicating that creatine can act as a direct scavenger of 
a range of radicals, including superoxide anion and peroxynitrite.17,18 This 
effect happens regardless if creatine is in or out a mammalian cell.19  This is in 
agreement with previous studies from our group that showed that creatine can 
act as an antioxidant, preventing the lipid peroxidation in rats submitted to 
intrastriatal injection of GAA 21. 
In summary, our findings demonstrated that intrastriatal administration of 
GAA affected antioxidants enzymes and caused an increase in the production 
of reactive species. Furthermore, the activity of the enzyme AChE suffered an 
increase. Therefore, it is possible to hypothesize that the alteration of this 
important enzyme for memory and cognition associated with changes in 
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parameters of oxidative stress may contribute to brain damage causing 
behavioral and cognitive deficits like the one observed in this study. If this also 
occurs in GAMT deficiency patients, it is possible that creatine supplementation 
might be beneficial as a form of adjunct treatment.   
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 3.10 Figure Legends 
Figure 1. Effect of GAA intrastriatal infusion and/or creatine 
administration on the novel object recognition test. (a) Results in the 
training session (b) Results in the test session (c) Discrimination index. Data 
are expressed as mean±SD for 10-12 animals in each group.*p<0.05; 
**p < 0.01; as evaluated using one-way ANOVA followed by Tukey‘s post-
hoc test. Cr: Creatine; GAA: Guanidinoacetate. 
Figure 2. Effect of GAA intrastriatal infusion and/or creatine 
administration on AChE activity in striatum of 60-day-old rats. Data are 
expressed as mean±SD for 7-10 animals in each group. **p < 0.01; as 
evaluated using one-way ANOVA followed by Tukey‘s post-hoc test. AChE: 
Acetycholinesterase; Cr: Creatine; GAA: Guanidinoacetate. 
Figure 3. Effect of GAA intrastriatal infusion and/or creatine 
administration on SOD activity in striatum of 60-day-old rats.  Data are 
expressed as mean±SD for 7-10 animals in each group. **p < 0.01, ***p<0,001; 
as evaluated using one-way ANOVA followed by Tukey‘s post-hoc test. SOD: 
Superoxide dismutase; Cr: Creatine; GAA: Guanidinoacetate. 
Figure 4.  Effect of GAA intrastriatal infusion and/or creatine 
administration on CAT activity in striatum of 60-day-old rats. Data are 
expressed as mean±SD for 7-10 animals in each group. **p < 0.01; as 
evaluated using one-way ANOVA followed by Tukey‘s post-hoc test. CAT: 
Catalase; Cr: Creatine; GAA: Guanidinoacetate. 
  
 
43 
 
Figure 5. Effect of GAA intrastriatal infusion and/or creatine 
administration on the oxidation of DCF in striatum of 60-day-old rats. Data 
are expressed as mean±SD for 7-10 animals in each group. **p < 0.01; as 
evaluated using one-way ANOVA followed by Tukey‘s post-hoc test. DCF: 2′,7′-
dichlorofluorescein; Cr: Creatine; GAA: Guanidinoacetate. 
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4.     CONCLUSÃO 
 
Em resumo, nossos resultados demonstraram que a administração 
intraestriatal de GAA apresentou um efeito considerável nas atividades de 
enzimas antioxidantes (SOD e CAT) além de aumentar a produção de espécies 
reativas (medido através da oxidação do DCF). Além disso, houve um aumento 
na atividade da enzima AChE. Assim sendo, é possível levantar a hipótese que 
a alteração dessa importante enzima para a memória e cognição, associada as 
mudanças nos parâmetros de estresse oxidativo podem contribuir para o dano 
cerebral, causando déficits comportamentais e cognitivo como o observado 
neste estudo. Se isso de fato ocorre em pacientes com deficiência na enzima 
GAMT, é possível que a suplementação com creatina possa apresentar 
benefícios como tratamento adjuvante.  
 
5.     PERSPECTIVAS 
● Avaliar conteúdo de BDNF em estriado de ratos submetidos à injeção 
instraestriatal de GAA; 
● Avaliar função mitocondrial (massa e potencial) e níveis de ATP em ratos 
submetidos à injeção instraestriatal de GAA; 
● Avaliar expressão gênica e imunoconteúdo de AChE em estriado de 
ratos submetidos ao modelo de injeção intraestriatal de GAA; 
● Avaliar a captação de glutamato e o imunoconteúdo dos seus 
transportadores (GLAST e GLT-1) em ratos submetidos à injeção 
instraestriatal de GAA; 
● Avaliar marcadores inflamatórios (IL-6 e TNF-α, IBA1) em ratos 
submetidos à injeção instraestriatal de GAA; 
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 ANEXO A - REVIEW INTITULADO "Guanidinoacetate Methyltransferase 
Deficiency: A Review of Guanidinoacetate Neurotoxicity" 
Abstract 
Guanidinoacetate Methyltransferase (GAMT) deficiency is an autosomal 
recessively  inherited  disorder  of  the  metabolism  of  creatine  that  leads  to 
depleted levels of creatine and excessive concentrations of guanidinoacetate. 
Patients affected develop neurological symptoms during childhood, such as 
muscular   hypotonia,   involuntary   extrapiramidal   movements,   convulsions, 
slurred speech, and even autism. Although the pathophysiology of GAMT- 
deficiency  is  unclear,  neurological  dysfunction  is  commonly  found  in  this 
disease  and  it  has  been  mainly  attributed  to  reduction  of  creatine  or/and 
increase of guanidinoacetate levels. Reports from literature suggest that 
guanidinoacetate may interfere with neuronal GABAA receptors and cause 
epilepsy in man. Preclinical studies show that guanidinoacetate increases free 
radical formation and decreases brain antioxidant defenses, inducing alteration 
in oxidative status.  Guanidinoacetate also impairs energy metabolism in brain. 
The discussion of this review focuses on various and latest studies addressing 
GAMT deficiency, creatine metabolism, as well as addresses the question of 
neurotoxicity guanidinoacetate. 
 
 
 
Key words: Guanidinoacetate Methyltransferase – GAMT Deficiency; 
Creatine; Guanidinoacetate; Neurotoxicity.
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Guanidiniacetate and creatine metabolism — an overview 
 
Guanidinoacetate (GAA) is a metabolite of glycine in which the amino 
group can be converted into a guanidine. It is highly involved in the metabolism 
of creatine, being its direct precursor. 1   
Creatine   has   been   known   for   its   essential   functions   in   muscle, 
contributing to a transient intracellular storage of metabolic energy mainly in the 
form of phosphocreatine that is nothing more than creatine with a phosphate 
group.1 Mammals take about half of their creatine from diet (mostly from meat 
and fish), and synthesize the other half through a relative simple reaction that 
occurs mainly in the kidney and liver involving a two-step pathway with two 
enzymes and one membrane carrier.² The enzymes involved are L-arginine: 
glycine amidinotransferase (AGAT) and N-guanidinoacetate methyltransferase 
(GAMT), while the membrane carrier is named SLC6A8. As suggested by the 
names of the relevant enzymes, this endogenous synthesis of creatine requires 
three amino acids, glycine, arginine and methionine.³ The first step of creatine 
biosynthesis is catalyzed by AGAT, and occurs mainly in kidney, more 
frequently in the mitochondria intermembrane space and in lower levels in the 
cytoplasm.4 It condenses the amino acids arginine and glycine to produce GAA. 
GAMT transfers a methyl group  from S-adenosylmethionine  (SAM)  to  GAA  
to  produce  creatine.  The majority of creatine that arise from this second step 
is produced in the liver.4 The creatine produced in the liver is secreted in the 
bloodstream by an unknown mechanism and
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distributed throughout the body, where it actively enters the cells using specific 
creatine transporter, SLC6A8, a Na+- and Cl− -dependent symporter.5,6 The 
phosphorylation of creatine is made possible by the creatine kinases (CK).7 This 
is an efficient way to store energy not only to skeletal muscle, but also to organs 
that require a great amount of energy in order to efficiently develop their 
activities in human body, like the brain.8 The phosphocreatine has a slightly 
higher diffusion capacity than ATP, and it can reversibly transfers its N-
phosphoryl group to ADP when this nucleotide is at high concentrations, 
regenerating ATP and preventing the tissue from running out of energy. 9, 10, 11. 
Approximately two thirds of creatine are transformed in phosphocreatine by the 
isoforms of CK,12 showing the importance of this molecule as intracellular 
storage of metabolic energy. Creatine and phosphocreatine may undergo a non 
enzymatic reaction of dehydration and cyclization to form creatinine that freely 
diffuses to the bloodstream and leaves the body in the urine. This molecule is 
frequently used as a marker of the renal function.13 Creatine synthesis is 
regulated physiologically in kidney by down-regulation of AGAT, and in 
developing brain cells  by  retro  regulation  of  AGAT  by  creatine  levels.14 
Creatine transporter (SLC6A8) is regulated by creatine levels in the 
bloodstream, and is inhibited by high levels of GAA.¹ Furthermore, the 
ingestion of creatine  supplement has been shown  to  decrease  the  rate  of  
endogenous  synthesis. 14
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GAMT deficiency 
 
In 1994, Stöckler et al, described a new inborn error of metabolism (IEM) 
that was adressed as the first inborn error of metabolism of creatine. The new 
disease was named after the affected enzyme: guanidinoacetate 
methyltransferase (GAMT) deficieny.15  This metabolic disease is an autosomal 
recessively inherited disorder caused by mutations in the GAMT gene that leads 
to depleted levels of creatine and excessive concentrations of GAA in skeletal 
muscle, blood, brain and other tissues.16,17,18  It  is  a  rare  disease  with  
approximately  110  cases reported so far, mostly from Europe and the Middle 
East.19 The cerebral tissue relies upon a continuous energy supply in order to 
maintain its functions properly. Therefore, with creatine in low levels, the brain 
becomes the most affected organ in GAMT deficiency patients. Neurological 
symptoms are common and variable among individuals affected by GAMT 
deficiency, including intractable epilepsy, intellectual impairment, autism, auto 
mutilating behavior, extra pyramidal syndrome, slurred speech and hypotonia. 
16,17,20,21 
Supplementation with creatine has been used as pharmacological 
treatment in GAMT deficiency for a long time.17 Nonetheless, one of the major 
issues surrounding GAMT deficiency and the brain is the difficulty that creatine 
has to penetrate the blood brain barrier (BBB) due to the small amount of SLC6A8 
transporter present in the microcapillaries, the absence of the same transporter in 
astrocytes lining them, and the limited diffusion of creatine through extracellular 
ma t r i z  su r rou nd in g  BB B .22 To provide sufficient  levels of creatine in
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healthy individuals, the brain has its own synthesis expressing AGAT and 
GAMT locally. In the cortex and other brain regions, AGAT and GAMT are 
dissociated and the intermediate GAA has to be transported between AGAT- 
and GAMT-expressing cells to complete the synthetic pathway.23 The presence 
of this endogenous creatine synthesis is supported by studies that 
demonstrated that despite the inability to capture creatine from periphery,  
patients with SLC6A8 deficiency still have  normal levels of  this molecule  in  
their central nervous system (CNS), while GAMT deficiency patients 
presented a dramatic reduction in comparison.24 The phenotypic diversity in 
patients with GAMT deficiency may be partially explained by the variety of 
functions that creatine seems to play in the brain. Apart from its functions in 
energy regeneration, researchers proposed that creatine may act as a 
neurotransmitter in the CNS modulating GABAergic and/or glutamatergic 
neurons.25 This theory is supported by studies that show that rat brain 
synaptosomes express creatine transporter SLC6A8,26  implying the existence 
of a creatine reuptake mechanism in axon terminal membrane.27 
The energetic reservoir provided by the system creatine/creatine kinase 
also helps to prevent overload of the mitochondrial respiratory chain, reducing 
generation of reactive species that have the power to cause oxidative stress 
and induce cytochrome C dissociation from the inner mitochondrial membrane, 
initiating early apoptotic triggering events.28 In fact, several studies claim that 
creatine  can  not only prevent the  generation of  reactive species, but also 
act as a direct scavenger of a range of radicals, including
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superoxide anion and peroxynitrite.29,30 This effect happens regardless if creatine is 
in or out a mammalian cell.31  A recent study revealed that creatine is able to 
prevent damage induced in  vitro  by  oxidizing  agents  in  both  nucleated  and  
non-nucleated  cells, suggesting   that   creatinine   may   possess   similar   
properties.32 These antioxidant proprieties presented by creatine appear to be 
beneficial not only to GAMT,33 but also to other innate errors of metabolism where 
creatine was able to prevent lipid peroxidation and imbalance of redox 
homeostasis.34,35 
 
Neurotoxicity of GAA 
 
Despite the fact that decreased levels of creatine play a key role in the 
physiopathology of    GAMT  deficiency,  the  evidence  shows  that  elevated 
levels of GAA in the brain is the major responsible for triggering the neurological 
symptoms of patients affected by this disease, particularly the epileptogenic 
action.21  Under physiological conditions, no transport of GAA occurs at the BBB, 
but there is a way out via taurine transporters  in  the  Blood  Cerebrospinal  Fluid  
Barrier  (BCSFB).22 Under GAMT deficiency there is uptake of GAA from the 
periphery at BBB, and the exit of GAA from CSF to blood may be increased using 
both TauT and SLC6A8 which is also capable of transporting GAA.22,29 The 
accumulation of GAA also happens via the brain endogenous AGAT activity, that is 
plainly functional. It is suggested that high concentrations of GAA can interfere  
with neuronal GABAA receptors but not GABAB-receptors and cause the 
neurological dysfunction behind the symptoms presented by GAMT deficiency 
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patients.36 GAA seems to act as a direct agonist of GABAA receptors with a less 
efficient GABA-mimetic potential than GABA itself. However, at high 
concentrations, like the ones found in GAMT patients, GAA is able to cause chronic 
stimulation in GABAA and, consequently, receptors undergo desensitization. This 
effect causes an increase in neuronal excitability due to internalization of GABAA 
receptors and a decreased response to GABA.37,38  The basal ganglia output 
nuclei globus pallidus and substantia nigra pars reticulata are involved in both 
movement and seizure control through GABAergic projections that appear altered 
in experiments conducted in vitro.37 Therefore, the motor dysfunctions and 
particularly seizure activity in patients with GAMT deficiency may be explain by 
interference of GAA in these interconnections present in the basal ganglia. 
In addition, studies have shown that an intrastriatal injection of GAA in 
rats leads to a series of biochemical alterations and abnormalities in behavioral 
tests. Firstly, the intraestriatal injection appeared to cause a decrease in antioxidant 
defenses at the same time that inhibit the activity of crucial enzymes for the 
generation of energy in the CNS. These enzymes are Na+, K+-ATPase, complex II 
in the mitochondrial respiratory chain and creatine kinase.39,40 Nonetheless, the 
cholinergic system plays a crucial role in cognitive function, including memory, and 
results showed that GAA significantly increased acetylcholinesterase (AChE) 
activity and impaired retention of an inhibitory avoidance task, implying that GAA 
accumulation affects all steps of memory processing following distinct time-
dependent mechanisms.41 Furthermore,  another  study  showed  that GAA  
markedly  inhibited glutamate  uptake  by  striatum,  what  can  be  linked  to  the  
neurological dysfunction characteristic of GAMT-deficient patients, especially the 
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generalized convulsions.42 These series of heterogenic alterations  appear to be 
involved in the pathophysiology of the neurological features present in patients with 
GAMT-deficiency. 
Suggested mechanisms of neurochemical effects of GAA accumulation in 
brain are summarized in figure 1. 
Figure 1. 
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Clinical cases and possible treatments to GAMT deficiency 
The diagnosis of GAMT deficiency can be made based upon a series of tests  that  
include  creatinine  excretion  in  24-hour  urine,  Sakaguchi  staining reaction of 
guanidino compounds in urine samples, GAA excretion measured quantitatively, 
and magnetic resonance spectroscopy to detect accumulation of GAA   and   
depletion   of   creatine   in   the   brain.
43  
Measurements  of  G AMT  activity  are  
now  available  for  some  cell  types.
44 Once the pathology is confirmed, the 
treatment of GAMT deficiency aims for both repletion of cerebral creatine and 
reduction of GAA concentrations. 
Oral supplementation with creatine (administered as creatine- monohydrate) 
at high doses can restore brain levels and result in improvements to the patients 
mostly in the involuntary extrapiramidal movements and convulsions.16,17 The 
benefits of this supplementation can be reached only with long term treatment due 
to the slow cross of creatine through BBB. The positive effects may take months 
or even years to appear. The doses used are normally around 400 mg-2g/kg/ day. 
This dose appears to be safe, since excess of creatine may cause oxidative 
stress.32 A pre-supplementation investigation of kidney function might be 
considered for reasons of safety, but in normal healthy subjects appears 
unnecessary.45 A recent study performed by Peters et al. (2015) showed that the 
supplementation  with creatine (3 g  per  day)  decreases  GAA  concentrations  in  
plasma  of  Bangladeshi adults without GAA deficiency.46 However, It is important 
to highlight that creatine supplementation  per  se  do not  fully normalize  GAA 
levels  in patients with GAMT deficiency. In order to achieve an even better clinical 
outcome, studies suggest that lowering the ingestion of one of the precursor 
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substrates of GAA, arginine, as well as high-dose L-ornithine supplementation 
are necessary.16,47,48 L- ornithine acts via competitive inhibition of AGAT. 
Furthermore, sodium benzoato administration may reduce the production of GAA 
via conjugation with glycine to form hippuric acid that is quickly excreted.18 
Nonetheless, a recent treatment applied in a 6 year old GAMT deficiency patient 
showed no further benefits of using sodium benzoato combined with creatine and 
arginine restriction, which questions the relevance of this additional 
supplementation.49 
This   evidence-based   treatment   using   creatine,   ornithine,   and sodium 
benzoate supplements along with dietary protein restriction was able to improve 
seizures and development in five patients with GAMT deficiency.50 The  average  
age  of  diagnosis  in  this  study  was 25.8 ± 26.2 months, but one of the 
subjects was diagnosed earlier, at 8 days from birth. The remarkable fact is 
that this subject  treated at birth remains developmentally  normal  at  12 
months  of  age,  while  the  others  still  face neurological dysfunctions. This is 
in agreement with adult and child cases of GAMT deficiency, where diagnosis 
and treatment later in life correlates with persistency    of    motor    and    
neurological    impairments,    despite    minor improvements.
 49,51,52 
A larger study collected data on 48 patients with GAMT deficiency 
worldwide,48 and showed that the clinical presentation of this innate error of 
metabolism is indeed highly variable, and best treated with supplementation with 
creatine and L-ornithine, and low intake of arginine. The median age at diagnosis in 
this study was 51 months, and then again, those who were diagnosed earlier in life 
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developed normally or showed only borderline developmental outcomes than those 
who were not. This may be due to the fact that BBB in developmental brain is not as 
tightly regulated as in adults, and this can  facilitate the cross of exogenous 
creatine into the brain. Furthermore, 3D organotypic brain cell cultures were heavily 
affected by increased levels of GAA, that caused axonal hypersprouting and an 
increase in non-apoptotic cell death.14 This strongly affects brain cell development in 
an irreversible way and may explain why later diagnosis fails to normalize completely 
the symptoms presented by GAMT deficiency patients. 
 
Although  early  treatment  seems  to  prevent  permanent  damage  from 
occur during CNS development, it is important to note that treatment should 
continue through lifetime, as we can see in the case of one of the patients in the 
study conducted by Stockler et al., 2014. Treatment was started within the first3 
weeks  of  life. At 32  months  her  development  was  normal  while  her  late 
treated brother (who also have GAMT deficiency) faced more difficulties. However,  
at  age  four  year  the  treatment  was  discontinued,  and  she  was affected by 
episodes of febrile seizures. She recommenced the treatment, and even though 
her current status is not as good as in the beginning of treatment, it is still better 
than her late-treated brother. This provides evidence of the importance of 
searching for new Prenatal Diagnosis of GAMT, like measurements in the amniotic 
fluid and direct sequencing of the GAMT gene in newborns.53,54 
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Conclusion 
 
In conclusion, GAMT deficiency is a rare innate error of metabolism of 
creatine that results in severe neurological effects. It is a treatable disorder, 
since supplementation with creatine, depletion of arginine in the diet, and 
supplementation with ornithine considerably  ameliorates the symptoms. The 
seizures do not respond to conventional epileptic treatment and there still 
controversy about the effectiveness of using sodium benzoate supplementation. 
Moreover, early diagnosis and start of treatment improve the outcome, and may 
even lead, if begun pre-symptomatically, to normal development. Ideally, treatment 
should start before the creatine pool supplied from maternal body during gestation 
ends. This makes GAMT deficiency an important target to pre- natal diagnosis. The 
treatment must be uninterrupted and always guided by health professionals in 
order to avoid nutritional deficits and low compliance. Nevertheless, a lot of study is 
still needed to better understand the mechanism behind all the neurological 
dysfunctions presented by patients, and finding a better way to remove brain 
GAA is the main goal of researches in the field. 
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Legends: 
 
 
 
Figure 1. Suggested mechanisms of neurochemical effects of GAA accumulation in brain. 
Under GAMT deficiency there is uptake of GAA from the periphery and GAA synthesis in 
the neuron occurring mainly in the mitochondria intermembrane space via AGAT. GAA 
leaves the neuron through an unknown mechanism and due to the lack of functional GAMT 
it accumulates in the synaptic cliff and within the neuron itself. This accumulation leads to a 
series of imbalances in enzymes, receptors and redox state. GAA seems to act as a direct 
agonist of GABAA receptors, leading to their desensitization and internalization. It appears 
to cause a decrease in antioxidant defenses at the same time that inhibits the activity of 
crucial enzymes for energy generation: Na+, K+-ATPase, complex II in the mitochondrial 
respiratory chain and creatine  kinase.  GAA significantly  increased  AChE  activity,  
leading  to  less  ACh available in the synaptic cliff. Furthermore, GAA markedly 
inhibited glutamate uptake by astrocytes. 
 
 
 
 
 
 
 
 
 
